Royal Bournemouth Hospital

PlaqueTec recruits first ten patients in BIOPATTERN trial

Retrieved on: 
Wednesday, November 29, 2023
Stem Cells, Medical Supplies, Practice Management, FDA, Physical Therapy, Diabetes, Managed Care, General Health, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Hospitals, Health Technology, Biometrics, Genetics, Fitness & Nutrition, Cardiology, Biotechnology, Health, Safety, Mallinckrodt, Royal Bournemouth Hospital, MHRA, Disease, World Heart Federation, Risk, Protein, CAD, Patient, Medicine, Research fellow, Death, NHS, Bristol Royal Infirmary, LBS, Royal Papworth Hospital, Coronary artery disease, Harvard Medical School, CVD, Health care, Liquid biopsy, JACC, Pharmaceutical industry, Medical imaging, Medical device

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Key Points: 
  • PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
  • The BIOPATTERN trial will use PlaqueTec’s proprietary blood sampling device, the Liquid Biopsy System™ (LBS), to collect samples at multiple sites along a patient’s diseased coronary artery.
  • Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples.
  • The trial aims to recruit 300 patients with established CAD who have been scheduled for a coronary angiogram.

VitalHub Announces Three-Year Expansion Licensing Contract With University Hospitals Dorset NHS Foundation Trust

Retrieved on: 
Monday, March 21, 2022
Company, Toronto Stock Exchange, Regional health authority, Population, VHI, NHS, Risk, Growth, Ministry of Children, Community and Social Services, Community, Royal Bournemouth Hospital, Mental health, Poole Hospital, Electronic health record, Corporation, Hip, Nursing care plan, CEO, United States Department of Health and Human Services, Failure, Human services, Social services, Case management, Bournemouth, Christchurch and Poole, TSX, Home health, University Hospitals Cleveland Medical Center, Christchurch Hospital, Technology, EHR, In Touch, University Hospitals Dorset NHS Foundation Trust, GLOBE, Phrase, Emergency Care Coordination Center, Trauma, Trust, Pharmaceutical industry, Hospital, Risk management, Health, Hospital

TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSX: VHI) is pleased to announce a three-year expansion licensing agreement of subsidiary Intouch with Healths (Intouch) patient flow solutions with University Hospitals Dorset NHS Foundation Trust (the Trust or Dorset).

Key Points: 
  • TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSX: VHI) is pleased to announce a three-year expansion licensing agreement of subsidiary Intouch with Healths (Intouch) patient flow solutions with University Hospitals Dorset NHS Foundation Trust (the Trust or Dorset).
  • University Hospitals Dorset NHS Foundation Trustmanages three hospitals inSoutheast Dorset.
  • It was formed following the merger ofPoole Hospital NHS Foundation TrustandThe Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust.
  • Expansion agreements such as this contract with University Hospitals Dorset NHS Foundation Trust affirm the value our customers derive from our products and services, said Dan Matlow, CEO of VitalHub Corp. With this deal, we expand upon our strong existing footprint across the NHS.

VitalHub Corp. Announces Multi Year Licensing Agreement With University Hospitals Dorset NHS Foundation Trust to Support New NHS Initiative

Retrieved on: 
Wednesday, July 14, 2021
Dorset, NHS Foundation Trusts, England, University Hospitals Dorset NHS Foundation Trust, National Health Service, Poole Hospital, Christchurch Hospital, Dorset, Royal Bournemouth Hospital

TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSXV: VHI) is pleased to announce the closing of a multi-year licensing agreement with University Hospitals Dorset NHS Foundation Trust (the Trust or Dorset) in support of the initial deployment of the novel NHS Thing Big initiative.

Key Points: 
  • TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSXV: VHI) is pleased to announce the closing of a multi-year licensing agreement with University Hospitals Dorset NHS Foundation Trust (the Trust or Dorset) in support of the initial deployment of the novel NHS Thing Big initiative.
  • Dorset is a newly-formed Trust, established through the merger of Poole Hospital Trust and Royal Bournemouth & Christchurch Trust, in October, 2020.
  • This agreement marks an expansion in the Companys continued growth across NHS hospitals and will span a three-year term.
  • University Hospitals Dorset NHS Foundation Trust, established in late 2020, has three hospital sites.